Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from NeOnc Technologies Holdings, Inc. ( (NTHI) ) is now available.
On July 8, 2025, NeOnc Technologies Holdings, Inc. announced a non-binding term sheet with Quazar Investment to establish a UAE-based investment and clinical platform targeting the MENA region. This partnership, involving a $50 million equity investment, will facilitate the formation of NuroMENA Holdings Ltd and its subsidiary NuroCure, which will manage clinical trials for NeOnc’s late-stage drug candidates in the region. Leveraging the UAE’s clinical trial infrastructure, the collaboration aims to advance treatments for aggressive brain cancers, marking NeOnc’s first international expansion and potentially enhancing its industry positioning.
More about NeOnc Technologies Holdings, Inc.
NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on developing and commercializing central nervous system therapeutics. The company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. NeOnc’s NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials, advancing under FDA Fast-Track and Investigational New Drug (IND) status.
Average Trading Volume: 67,889
Learn more about NTHI stock on TipRanks’ Stock Analysis page.